How Sequencing Technology and Workflows Are Shaping the Clinical Oncology Next Generation Sequencing Market

The clinical oncology next generation sequencing market is built on a technology that sequences thousands of DNA molecules in parallel, delivering qualitative and quantitative data at high speed and throughput. According to Polaris Market Research, the global market was valued at USD 477.16 million in 2024 and is projected to reach USD 2,208.79 million by 2034, growing at a CAGR of 16.58% from 2025 to 2034. This article looks at the clinical uses, platforms, and technology segments that determine how laboratories adopt next generation sequencing (NGS) in cancer care.

Core Clinical Uses in Oncology

NGS supports several main clinical applications in oncology. Tumor profiling identifies actionable mutations, liquid biopsy enables minimally invasive detection and real-time monitoring of tumor dynamics, and minimal residual disease monitoring tracks treatment response and disease recurrence. NGS is also used in tests that match patients with targeted therapies.

The rising prevalence of cancer is a central driver. The World Health Organization stated that over 35 million new cancer cases are predicted by 2050, a 77% increase from the estimated 20 million cases in 2022. That growth is pressuring clinicians to use advanced genomic profiling to identify targetable mutations and guide therapy decisions, which encourages NGS adoption.

Scaling Up Cancer Genomic Profiling

High-throughput platforms allow laboratories to process multiple tumor samples simultaneously, reducing turnaround times and making large-scale cancer genomic profiling feasible for routine clinical use. They can sequence more genes at lower cost and improve the detection of rare mutations and complex genomic alterations, which supports treatment personalization. As high-throughput platforms streamline workflows and enhance data quality, hospitals and research institutions are integrating NGS into standard oncology practice.

Healthcare spending adds support. The American Medical Association stated that health spending in the U.S. increased by 7.5% in 2023 to $4.9 trillion. Larger healthcare budgets enable hospitals and clinics to adopt advanced oncology diagnostics, making NGS accessible to a broader patient population.

Technology and Workflow Segments

By technology, the report covers whole genome sequencing, whole exome sequencing, and targeted sequencing & resequencing. The targeted sequencing & resequencing segment accounted for 64.93% of revenue in 2024 owing to its cost-effectiveness, high depth of coverage, and ability to focus on specific genes or genomic regions. It offers faster turnaround and reduces data complexity compared with broader methods, which makes it well suited to routine clinical use. Widely available cancer-specific gene panels and the use of the technology by pharmaceutical companies to stratify patients in clinical trials also boosted adoption.

By workflow, the market is divided into pre-sequencing, sequencing, and data analysis. The sequencing segment held a 57.03% revenue share in 2024 because of demand for high-throughput, accurate, and cost-efficient platforms capable of analyzing cancer genomes with greater precision. The proliferation of cancer and the increasing use of liquid biopsy-based testing further drove demand for sequencing. Data analysis remains a pressure point: the complexity of data analysis and interpretation hinders demand for NGS in clinical oncology, while companies are investing in AI-driven data analysis and multi-omics integration to maintain a competitive edge.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/clinical-oncology-next-generation-sequencing-market 

Competitive Landscape and Recent Developments

Illumina, Inc. and Thermo Fisher Scientific dominate the industry with their sequencing platforms, extensive reagent portfolios, robust bioinformatics pipelines, and strong partnerships with academic and clinical institutions. F. Hoffmann-La Roche Ltd. also holds a significant position, leveraging its acquisition of Foundation Medicine to offer comprehensive genomic profiling tests such as FoundationOne CDx, which is FDA-approved.

In February 2025, Roche unveiled its sequencing by expansion (SBX) technology for decoding complex diseases such as cancer, immune disorders, and neurodegenerative conditions. In August 2024, Illumina announced its oncology menu for NovaSeq X Series customers, enabling labs to expand oncology testing research of tissue and liquid biopsy samples.

The report lists Agilent Technologies, Eurofins Scientific S.E., F. Hoffmann-La Roche Ltd., Illumina, Inc., Myriad Genetics, Oxford Nanopore Technologies Ltd., Pacific Bioscience, Perkin Elmer, Qiagen N.V., and Thermo Fisher Scientific among the major companies in the clinical oncology next generation sequencing market.

Conclusion

The clinical oncology next generation sequencing market is expected to witness significant growth, driven by increasing adoption of precision medicine and molecular profiling in cancer diagnosis and treatment planning. Advancements in sequencing technologies and growing demand for comprehensive genomic analysis are supporting the integration of next generation sequencing into clinical oncology workflows. Increasing applications in biomarker identification, targeted therapy selection, and disease monitoring are further strengthening market demand. However, high testing costs, complex data interpretation, and reimbursement limitations may challenge broader implementation. Continued development of bioinformatics tools, liquid biopsy applications, and clinically validated genomic tests is expected to create new opportunities. Overall, the market is anticipated to advance as healthcare providers increasingly focus on personalized cancer care and evidence-based treatment decisions.

More Trending Latest Reports By Polaris Market Research:

Radar Sensor Market

Genomic Data Set for Real World Evidence (RWE) Applications Market

Surface Mount Technology Market

T4 DNA Ligase Market

Genomic Data Set for Real World Evidence (RWE) Applications Market

Substation Automation Market

Linerless Labels Market

The Slide into Success: Why Slider Bags Are Taking the Industry by Storm

Consumer Packaged Goods Market